SMIM21: A Potential Drug Target and Biomarker for Disease (G284274)

Target Name: SMIM21

NCBI ID: G284274

SMIM21

SMIM21: A Potential Drug Target and Biomarker for Disease

SMIM21 (SMI21_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the superfamily of transmembrane protein (SMP) family, which includes proteins that are involved in various cellular processes, including signaling pathways, ion transport, and cytoskeletal organization.

SMIM21 is of particular interest as a potential drug target, due to its involvement in several disease processes. For example, it has been shown to be involved in the development and progression of several neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders. Additionally, it has been linked to the development of cardiovascular disease, including myocardial infarction and stroke.

SMIM21 is also of interest as a biomarker, due to its potential utility in diagnostic tests for these diseases. The protein is expressed in various tissues of the body, including the brain, and can be used as a protein biomarker for disease diagnosis and monitoring. This is because the expression of SMIM21 is often affected by the underlying cellular and molecular mechanisms that are driving the disease, which can provide information about the progression of the disease and the effectiveness of potential therapeutic interventions.

One of the key challenges in studying SMIM21 is its complex cellular and molecular mechanisms. Because it is involved in a wide range of cellular processes, it is difficult to understand exactly how it contributes to the development and progression of disease. However, research into its role in these processes has identified several key players, including signaling pathways, ion transport, and cytoskeletal organization.

SMIM21 is involved in several signaling pathways that are involved in the development and progression of disease. For example, it has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these disorders.

Additionally, SMIM21 has been shown to be involved in the development of cardiovascular disease, including myocardial infarction and stroke. These conditions are characterized by the blockage of blood flow to the heart or the brain, which can lead to tissue damage and death.

SMIM21 is also involved in several ion transport processes that are important for maintaining the electrical activity of cells. For example, it is involved in the regulation of sodium and potassium ions in the brain, which are important for maintaining the normal flow of electrical signals through the brain. The regulation of these ions is critical for the function of the brain, and alterations in their levels or patterns can contribute to the development of neurological disorders.

Finally, SMIM21 is involved in several cytoskeletal organization processes that are important for maintaining the structure and function of cells. For example, it is involved in the regulation of actin filaments, which are important for the structure and stability of actin filaments in the cytoskeleton. The cytoskeleton is a complex network of filaments and other structures that provide support and structure to cells, and alterations in its structure and function can contribute to the development of diseases such as cancer and neurodegenerative disorders.

In conclusion, SMIM21 is a protein that is involved in a wide range of cellular and molecular processes that are important for the development and progression of disease. Its involvement in these processes makes it an attractive target for drug development and diagnostic tests. Further research is needed to fully understand the role of SMIM21 in disease, and to develop effective therapeutic interventions.

Protein Name: Small Integral Membrane Protein 21

The "SMIM21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMIM21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets